Biovaxys Technology Corp (5LB)

Frankfurt
Currency in EUR
0.032
0.000(0.00%)
Delayed Data
5LB Scorecard
Full Analysis
Stock has taken a big hit over the last week
Fair Value
Day's Range
0.0320.032
52 wk Range
0.0200.072
Key Statistics
Edit
Bid/Ask
0.035 / 0.054
Prev. Close
0.032
Open
0.032
Day's Range
0.032-0.032
52 wk Range
0.02-0.072
Volume
1
Average Volume (3m)
35.58K
1-Year Change
-23.44%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
5LB Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Biovaxys Technology Corp Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune-educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. Its product pipeline includes Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, which is in phase I clinical stage to treat the MAGE protein family member A9 in human cancers. It also develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health’s proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. In addition, the company operates T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX™ formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies, namely those triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

Compare 5LB to Peers and Sector

Metrics to compare
5LB
Peers
Sector
Relationship
P/E Ratio
−5.2x−1.3x−0.6x
PEG Ratio
−0.06−0.050.00
Price/Book
−75.3x0.1x2.6x
Price / LTM Sales
-0.4x3.1x
Upside (Analyst Target)
-42.5%55.1%
Fair Value Upside
Unlock21.5%9.2%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Biovaxys Technology (5LB) Stock Price Today?

The Biovaxys Technology stock price today is 0.032

What Stock Exchange Does Biovaxys Technology Trade On?

Biovaxys Technology is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for Biovaxys Technology?

The stock symbol for Biovaxys Technology is "5LB."

What Is the Biovaxys Technology Market Cap?

As of today, Biovaxys Technology market cap is 12.72M.

What is Biovaxys Technology Earnings Per Share?

The Biovaxys Technology EPS is -0.021.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.